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Abstract
Dendritic cells (DCs) play dual roles in innate and adaptive immunity based on their functional maturity, and both innate and
adaptive immune responses have been implicated in myocardial tissue remodeling associated with cardiomyopathies.
Peripartum cardiomyopathy (PPCM) is a rare disorder which affects women within one month antepartum to ﬁve months
postpartum. A high occurrence of PPCM in central Haiti (1 in 300 live births) provided the unique opportunity to study the
relationship of immune activation and DC maturation to the etiology of this disorder. Plasma samples from two groups
(n ¼ 12) of age- and parity-matched Haitian women with or without evidence of PPCM were tested for levels of biomarkers of
cardiac tissue remodeling and immune activation. Signiﬁcantly elevated levels of GM-CSF, endothelin-1, proBNP and CRP
and decreased levels of TGF-b were measured in PPCM subjects relative to controls. Yet despite these ﬁndings, in vitro
maturation of normal human cord blood derived progenitor dendritic cells (CBDCs) was signiﬁcantly reduced (p , 0.001) in
the presence of plasma from PPCM patients relative to plasma from post-partum control subjects as determined byexpression
of CD80, CD86, CD83, CCR7, MHC class II and the ability of these matured CBDCs to induce allo-responses in PBMCs.
These results represent the ﬁrst ﬁndings linking inhibition of DC maturation to the dysregulation of normal physiologic
cardiac tissue remodeling during pregnancy and the pathogenesis of PPCM.
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Introduction
Peripartum cardiomyopathy (PPCM) is a rare disease
in the United States with a reported incidence
between 1:3 000 and 1:15 000 pregnancies (Ventura
et al. 1997, Brown and Bertolet 1998). The four
primary diagnostic criteria are (a) development of
cardiac failure in the last month of pregnancyor within
ﬁve months postpartum; (b) absence of an identiﬁable
cause for the cardiac failure; (c) absence of recogniz-
able heart disease prior to the last month of pregnancy
and (d) left ventricular dilatation and decreased
contractility demonstrated by echo criteria of
depressed fractional shortening (,30%) or ejection
fraction (,45%). Approximately 20% of women with
PPCM die unless they receive cardiac transplant.
During normal pregnancy increased hemodynamic
demand and environmental stress associated with late
stage pregnancy initiate physiological compensatory
responses that involve well-regulated homeostatic
structural remodeling of decidual and cardiovascular
tissues. Cellular components of the innate arm of the
immune system mediate such remodeling responses
by assisting in the clearance and resorption of dead or
dying cells and by helping to create supporting
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Under physiological conditions these cellular
responses are regulated in part by the coordinated
local release of speciﬁc chemokines, cytokines and
growth factors that form a gradient that leads to the
recruitment and development of bone marrow derived
progenitors which mediate tissue remodeling and
repair in the tissues secreting the mediators without
triggering unwanted immunopathology. Although, the
exact etiology of PPCM remains unknown, infectious,
inﬂammatory, genetic, hormonal and/or metabolic co-
factors may contribute to a disruption of these
physiologically regulated pregnancy-associated car-
diac tissue remodeling responses which if not reversed
leads to cardiomyopathy. It is to be noted that such
abnormalities are indeed reversible since a signiﬁcant
number of PPCM patients do return to normal
cardiac function. Thus, the reasons for these divergent
clinical outcomes identify one of the major issues that
needs to be determined.
Thus, we submit that the lack of a physiologically
normal remodeling response facilitates myocardial
tissue injury which can result in the release of certain
cryptic cardiac antigens, e.g. myosin, mitochrondrial
proteins, natriuretic peptides, heat shock proteins
(HSPs), etc. that can become exposed to immature
dendritic cells (DCs), which under the inﬂuence of
other “danger signals” present during the injury and
remodeling process (such as CD40L expressed on
activated platelets (Stumpf et al. 2003) undergo
maturation and become able to initiate subsequent
cardiac-speciﬁc auto-immune responses which may
contribute signiﬁcantly to further cardiac tissue injury.
Cardiac tissue remodeling can also be mediated by a
variety of endogenous stress induced proteins includ-
ing, TNF-a, IL-1, IL-6, endothelin-1, angiotensin II,
matrix metalloproteinases (Kai et al. 1998, Schwartz-
kopff et al. 2002, Altieri et al. 2003, Inoue et al. 2003,
Yamazaki et al. 2004), TGF-b, acidic and basic
ﬁbroblast growth factors, vascular endothelial growth
factor (VEGF) and others (Mann 2002a, b, 2003,
Zolk et al. 2002, Flesch et al. 2003) released locally by
cardiovascular tissues. These stress induced proteins
act directly on both cardiac myocytes to induce
hypertrophy, cytoprotection or repair, and on non-
myocyte cardiac tissues to increase vascularization and
to effect ECM remodeling and ﬁbrosis.
The recent identiﬁcation of a signiﬁcantly high
incidence and prevalence of PPCM among women in
the Hospital Albert Schweitzer (HAS) District in
central Haiti (Fett et al. 2002) presented an unusual
opportunity to study the potential mechanism(s) of
this disease. The objectives of the present study were
to (1) assess the role of innate immunity in the
pathogenesis of PPCM by characterizing differences
in the levels of stress-induced proteins associated with
innate immune-mediated tissue remodeling measured
in plasma isolated from Haitian PPCM patients
relative to age- and parity-matched Haitian mothers
without disease and (2) to measure the functional
potential of plasma from PPCM and control Haitian
subjects to induce the maturation of cord blood
derived progenitor dendritic cells (CBCDs) which we
reason is involved in the remodeling response. The
results presented herein indicate that despite signiﬁ-
cant elevation in plasma levels of biomarkers of
cardiac tissue remodeling and immune activation,
plasma from Haitian PPCM patients exhibit a
signiﬁcantly reduced potential for inducing DC
maturation, an event required for physiological tissue
remodeling, and thus for the ﬁrst time provide
evidence for a pathogenic role for DC function and
dysregulation of innate immunity in the etiology of
PPCM in this patient group.
Methods
Patients and clinical specimens
The subjects enrolled in the study were Haitian
mothers from the HAS District in Dechappelles,
Haiti, where a high incidence of PPCM has been
reported and a PPCM registry has recently been
established (Fett et al. 2002). The criteria for patient
enrollment in the HAS PPCM Registry are based on
the following case deﬁnition: (1) onset of congestive
heart failure during the period of one month before
delivery through ﬁve months postpartum; (2) absence
of preexisting heart disease; (3) no other identiﬁable
cause of congestive heart failure—this involves ruling
out other causes of CHF, including but not limited to
severe anemia, sepsis, severe toxemia of pregnancy,
tuberculosis or other pulmonary diseases, HIV-1,
beriberi heart disease or other nutritional deﬁciencies,
tocolytic agents or other toxic exposures, ﬂuid
overload, amniotic ﬂuid embolism, valvular heart
disease, coronary artery disease, hypertensive cardio-
vascular disease, thyrotoxicosis or other endocrino-
pathies and familial dilated cardiomyopathy and (4)
evidence of left ventricular dilatation with diminished
contractility characterized by an ejection fraction less
than 45% or fractional shortening less than 30% and
end-diastolic dimension more than 2.7cm/M
2 as
determined by echocardiography. In addition, the
following documentation was included for each
patient in the registry: history and physical exam,
New York Heart Association functional classiﬁcation
(I–IV), chest X-ray, echocardiogram, HIV serology
(positive serologies were excluded from the registry),
RPR as part of prenatal care, urinalysis, hematocrit
and an epidemiology questionnaire. Parity-matched
non-PPCM Haitian mothers from the same (HAS)
hospital district were selected from the Women’s
Health Registry and invited to participate in the study
as controls. Following informed consent, a 20ml
sample of whole blood was collected in vacutainer
J. E. Ellis et al. 266collection tubes containing EDTA as an anti-
coagulant. After centrifugation, the plasma was
aliquoted and stored at 2208C.
Human umbilical cord blood was collected follow-
ing delivery of term fetuses of mothers with no known
health or pregnancy related complications who
delivered at Grady Memorial Hospital in Atlanta,
GA. Cord blood was collected in sterile 50ml
centrifuge tubes containing 5ml of sterile Hank’s
buffered saline solution supplemented with 500 units
of sodium heparin and 2.5mg of gentamicin. The
blood was gently mixed and stored for less than 24h at
room temperature. Mononuclear cells were isolated
from umbilical cord blood by density gradient
centrifugation on lymphocyte separation medium.
CD34 þ cord blood stem cells (CBSCs) were then
positively separated in a magnetic ﬁeld using EasySep
immunomagnetic beads (Stem Cell Technologies,
Vancouver, BC), The collection of all clinical speci-
mens was conducted under established protocols
approved by IRBs at HAS and Emory University.
Determination of serum levels of biomarkers for heart
disease and innate immune activation
Plasma levels for a select group of biomarkers
associated with left ventricular remodeling, DC
maturation and innate immune activation, including
proBNP, C-reactive protein, endothelin-1, antibodies
to HSP 60 and 70, IL-1a, IL-1b, IL-4, IL-6, IL-10,
CD40L, GM-CSF, TNF-a and TGF-b,w e r e
measured using commercially available immunoassays
(Stressgen Biotechnologies Corp., Victoria BC,
Canada; Biosource International, Camarillo Califor-
nia; and APLCO, Windham, NH) according to their
manufacturer’s instructions.
Proliferation assays
Mature DCs, unlike immature progenitor DCs, richly
express MHC class II and select costimulatory
molecules, e.g. CD80 and 86, and based on the
spectrum of peptides bound to their MHC II
molecules are able to engage in contact dependent
interactions with cognate T cells resulting in readily
measurable T cell proliferation. Thus, in vitro co-
culture assays were used to assess the ability of plasma
from PPCM or control subjects to induce the
functional maturation of cord blood derived progeni-
tor immature DCs (prCBDCs) and following their
maturation assess their ability to induce (allo-)
proliferation of HLA miss-matched PBMC respon-
ders. Pooled CBDCs were developed from CD34 þ
stem cells (CBSCs) isolated from human cord blood
as described and then suspended at 10
6/ml in serum
free stem cell medium supplemented with 2mM
L-glutamine, and gentamicin (50mg/ml). To promote
the development of prCBDCs, stem cell medium was
supplemented with 2ng/ml GM-CSF; to promote the
development of mature CBDCs (positive controls),
stem cell medium was supplemented with GM-CSF
(10ng/ml), LPS (1mg/ml) IL-4 (10ng/ml), and TNF-
a (2 000U/ml); and to evaluate the effect of PPCM or
control plasma on prCBMC maturation, CBSCs were
cultured in stem cell medium supplemented with
2ng/ml GM-CSF and 25% (v/v) human plasma
isolated from (a) pooled fetal cord blood, (b) normal
non-Haitian—nulliparous adults, (c) normal age and
parity matched Haitian adult females or (d) Haitian
PPCM donors. For each culture condition CBSCs
were incubated in a humidiﬁed environment at 378C
with 7% CO2 for 4–7 days. CBDCs were then
harvested, counted and re-suspended at 10
5/ml in
RPMI media supplemented with 10% FBS without
recombinant growth factors. A total of 10
4 prCBDCs
was then placed in co-culture with 10
5 ﬁcol-
hypaque—puriﬁed allogeneic PBMCs from normal
donors in atotal volume of 0.2ml of media in triplicate
wells in round-bottomed 96-well tissue culture plates
then incubated as described for an additional 96h.
Each well was then pulsed with 1mCi/well of methyl-
[
3H]- thymidine (2Ci/mmol, NEN, Boston, MA) for
16h before harvesting and counting for 1min on a
Wallac MicroBeta TriLux liquid scintillation counter
(PerkinElmer Life Sciences, Boston MA). Controls
consisted of prCBDCs, CBDCs or PBMCs cultured
alone in media. Quantitative measurements of cell
proliferation (mean counts per minute [cpm]) were
normalized by subtracting mean cpm from cultures of
CBDCs without PBMCs.
Flow microﬂuorometry (fmf) analysis
Detection of cell surface-expressed antigens associ-
ated with a phenotype of either immature or mature
DCs was performed by FMF using ﬂuorochrome
conjugated mouse anti-human monoclonal antibodies
to HLA-DR, CD80, CD83, CD86 and CD11a
(CCR7). Aliquots of progenitor DCs were incubated
in individual 12 £ 75mm plastic tubes with 1mgo f
Phycoerythrin (PE) conjugated HLA-DR (MHC
Class II), MHC Class I, CD80, CD83, CD86 or
CCR7 (Becton Dickinson Immunocytometry Sys-
tems, Pleasantville, CA) in media for 30min on ice
then washed twice with Dulbecco’s PBS pH 7.4 and
immediately analyzed by FMF with a Becton
Dickinson FACS-Caliber using cellquest imaging
software.
Statistical analysis
Statistical analysis of replicate measurements of
independent samples taken at a single or multiple
time points was performed after descriptive tests
(e.g. the Shapiro–Wilk W test) were conducted to
verify that the observed measurements were normally
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independent normally distributed samples were
assessed by one way analysis of variance (ANOVA)
with contrasts and p values were assigned using
Tukey’s 95% conﬁdence intervals. Non-parametric
tests (Mann–Whitney rank sum tests) were employed
on all measurements where a normal distribution of
the observation was not assumed. All statistical
analyses was performed using Analyze-It software
V. 1.62 for Microsoft Excel (Leeds, UK).
Results
Baseline clinical proﬁles of haitian study subjects
The baseline clinical data for the PPCM (n ¼ 12) and
control (n ¼ 12) patients participating in this study
are presented in Table I. The range and median values
for age, time post-partum of plasma collection,
gravida, parity, left ventricular ejection fraction
(LVEF), LV end-diastolic diameter (LVEDD), LV
shortening fraction (LVSF), LV end-diastolic diame-
ter/meter-squared body surface area (EDD/M
2), and
New York Heart Association (NYHA) functional
classiﬁcation are presented for both study subject
groups. Non-parametrical analysis revealed that the
two study groups did not differ signiﬁcantly in age,
time of specimen collection post-partum, gravida, or
parity. However, as expected the PPCM subjects did
differ signiﬁcantly (p , 0.04) from control subjects in
their values for LVEFand LVEDD and in their NYHA
functional classiﬁcation.
Disease-speciﬁc differences in plasma levels of biomarkers
of inﬂammation and cardiac tissue remodeling
Brain Natriuretic Peptide (BNP) belongs to a family of
hormones which includes Atrial Natriuretic Peptide
(ANP), and C-type Natriuretic Peptide (CNP), all of
which are secreted by the atrium, ventricle and cardiac
microvascular endothelial cells(Suzuki et al. 2001).
BNP is derived from its high MW precursor, pro-BNP
(1–108 AA) and functions to regulate vascular tone
through a spectrum of hypotensive effects which
protect against ﬂuid overload and high blood pressure.
The mature form, BNP-32, consists of the 32 C-
terminal AA residues (77–108) of the parent pro-
BNP, both of which are stored in ventricular tissues.
It has been suggested that elevated plasma levels of
amino-terminal pro-BNP (Nt-pro-BNP) is a better
indicator of early cardiac dysfunction than BNP-32.
Plasma levels of pro-BNP for 12 PPCM patients and
12 control subjects used in this study are displayed in
Table II. Statistically signiﬁcant differences between
the two groups (p , 0.0001) was determined by both
one-way ANOVA and by independent samples t-test
as described in the methods section.
C-Reactive protein is an acute phase pentameric
globulin produced by the liver in response to
inﬂammation and tissue injury. Plasma levels have
been reported to be signiﬁcantly elevated in patients
with advanced DCM or lymphocytic myocarditis and
to correlate with acute left ventricular decompensa-
tion (Kaneko et al. 1999, 2002). Measurement of
plasma CRP values has also been shown to be a
predictor of improvement or readmission during heart
failure (Alonso-Martinez et al. 2002). Plasma levels of
CRP in Haitian PPCM patients (n ¼ 12) relative to
control subjects (n ¼ 12), measured by capture
ELISA as described in the methods section, were
found to be signiﬁcantly elevated (p , 0.002) by
ANOVA (Table II).
Stress due to hyperthermia or hypoxia can result in
the rapid denaturing of cellular proteins including
mitochrondrial proteins vital to cellular metabolism
and survival. HSPs are specialized proteins that
possess an intrinsic chaperone function and can
Table I. Baseline clinical data on PPCM and control subjects.
PPCM Control
Median Range n Median Range n
Age 25 17–40 12 28.5 16–38 12
Time post-partum (days) 49 19–101 12 128 65–194 12
Gravida 3.2 1–7 12 3 1–10 12
Parity 3 1–7 12 3 1–10 12
LVEF (%)*,† 25 15–30 12 50 40–55 12
LVEDD
†,‡ 6.15 5.2–7.2 12 4.1 4–5.6 12
LVSF
{ 15 5–24 12 30 20–35 12
EDD/M
§ 4.05 3.5–4.8 12 2.7 2.7–3.7 12
NYHA functional class
k III III–1V 12 I I 12
*LVEF ¼ left ventricular ejection fraction meets ppcm criteria if less than 45%, normal ¼ 50% and ..
†Values for PPCM signiﬁcantly different from control (p , 0.04).
‡LVEDD ¼ left ventricular end-diastolic diameter.
{LVSF ¼ left ventricular shortening fraction meets ppcm criteria if less than 30%, normal ¼ 35% and ..
§EDD/M
2 ¼ left ventricular end-diastolic diameter/meter-squared body surface area, normal 2.7cm/M
2 or less.
kNYHA ¼ New York Heart Association functional classiﬁcation.
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(denatured) proteins. The rapid expression of HSPs
in response to physiologic stress thus helps to protect
cells from injury (Hendrick and Hartl 1995, Bukau
and Horwich 1998). Interaction between HSP and
certain pattern recognition receptors (PRR) that
recognize conserved epitopes termed pathogen-
associated molecular patterns causes non-speciﬁc
activation and maturation of PRR- expressing
progenitor DCs (Kuppner et al. 2001). Through
such interactions HSPs are able to activate the innate
immune system. It has been proposed that such events
ultimately result in adaptive immune responses
manifested by the appearance of antibodies directed
against HSP and HSP associated cellular proteins
(Latif et al. 1993, Portig et al. 1997, Srivastava 2002a,
b). Elevated serum levels of certain HSPs, e.g. HSP60
and HSP70, as well as anti-HSP antibodies are
associated with cardiovascular diseases including
DCM (Latif et al. 1993, 1999, Knowlton et al.
1998, Mandi et al. 2000). The levels of antibodies to
HSP60 and HSP-70 were measured in plasma
samples from both PPCM and Control subjects as
described in the methods section. However, no
statistically signiﬁcant differences were detected
(Table II).
Disease-speciﬁc differences in plasma levels of biomarkers
of innate immune activation
Several stress-activated cytokines have been shown to
playimportantbiochemicalrolesininitiatingresponses
to cardiac tissue injury induced by increased hemody-
namic demands to preserve and maintain heart
function during environmental or physiological stress
(Mann 1996, Aukrust et al. 1999, Anker and von
Haehling 2004). Such cytokines are known to have
pleiotropiceffectsandmaypositivelyinﬂuence(IL-1b,
TNF-a, GM-CSF, IL-4, IFN-g) or negatively inﬂu-
ence (TGF-b and IL-10) maturation of progenitor
DCs. Prolonged activation or over-expression of such
cytokines may lead to pathological decompensation.
Plasma levels of a select group of these cytokines were
measured by capture ELISA as described in the
methodssectionandareshowninTableIII.Nodisease
speciﬁc differences were observed in plasma levels of
IL-1a, IL-4, IFN-g or IL-10. While elevated levels
of IL-1b (p , 0.06), TNF-a (p , 0.08) and sCD40L
Table III. Plasma levels of cytokines and growth factors involved in DC maturation.
Cytokine
IL-1b* (pg/m/) TNF-a* SCD40L* GM-CSF* TGF-b
†
Group Control PPCM Control PPCM Control PPCM Control PPCM Control PPCM
Disease-speciﬁc differences
n 12 12 12 12 12 12 12 12 12 12
Mean 0.00 2.75 1.27 2.03 0.00 2.13 0.00 2.74 0.76 0.58
t-Statistic 22.01 21.82 21.49 22.97 2.09
DF 22.0 22 22.0 22 22.0 22 20.0 22.0
Two-tailed t 0.06 0.08 0.15 0.0076
‡ 0.05
‡
Cytokine IL-1a (pg/m/)* IL-4 (pg/m/)* IFN-g* (pg/m/) IL-10†
Group Control PPCM Control PPCM Control PPCM Control PPCM
No-disease-speciﬁc differences
n 12 12 12 12 12 12 12 12
MEAN
t-statistic
DF 22 22 22 22 22 22 22 22
Two-tailed t ND ND ND ND
*Factors that promote DC maturation.
†Factors that suppress DC maturation.
‡Statistically signiﬁcant differences.
Table II. Biomarkers of inﬂammation and remodeling.
Endothelin I (pg/ml) proBNP (fmol/ml) CRP (Mg/ml)
Anti-HSP60*
(ng/ml)
Anti-HSP70*
(ng/ml)
Group Control PPCM Control PPCM Control PPCM Control PPCM Control PPCM
Mean 0.75 1.823 74.77 413.8 3.97 201.2 37.419 27.161 3.595 2.354
t-statistic 7.5 3.44 3.47
Two-tailed t ,0.0001 ,0.0054 ,0.0052 ND ND
*values represent plasma levels (ng/ml) of total antigen-speciﬁc IgG, IgA and IgM.
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values did not achieve statistical signiﬁcance. The only
2 cytokines that showed signiﬁcant differences were
elevated plasma levels of GM-CSF (p , 0.0076) and
diminished levels of TGF-b (p , 0.05) in PPCM
subjects relative to control subjects (Table III).
Allo-proliferative responses to cord blood derived
dendritic cells
It has been previously shown that chemokines attract
progenitor cells of the dendritic cell lineage (pDCs) to
sites of tissue injury and in the presence of select
cytokines and growth factors such pDCs develop into
mature DCs. Mature DCs richly express MHC class
II and the co-stimulatory molecules, such as CD80
and CD86 which supports their functional ability to
present cognate antigens and induce proliferative
responses in antigen speciﬁc T cells and proliferative
responses in allogeneic T cells in standard mixed
lymphocyte cultures. It was reasoned that if PPCM
patients were experiencing tissue injury such injury
could lead to the synthesis and release of cytokines and
growth factors in their plasma that would facilitate the
trafﬁcking, migration and maturation of pDCs into
fully competent functionally mature DCs. In order to
test this hypothesis, allo-proliferative responses of
PBMCs to cord blood derived prDCs cultured in the
presence of plasma from PPCM patients and for
purposes of control plasma from age and parity
matched Haitian women without evidence of heart
d i s e a s ew e r em e a s u r e di nM L R st oa s s e s st h e
functional maturation of CBDCs. To ﬁrst establish
the optimal kinetics and culture conditions for full
functional maturation of progenitor CBDCs in vitro,
puriﬁed cord blood derived CD34 þ cells were
incubated in serum-free stem cell media sup-
plemented with low dose (2ng/ml) GM-CSF alone
to promote the development of immature progenitor
DC or with high dose GM-CSF (10ng/ml) plus IL-4
(10ng/ml), TNF-a (10ng/ml) and LPS (1mg/ml) to
promote the development of mature DCs. After 4 and
7 days in culture, the cord blood cells were
resuspended in RPMI-10 media with 10% fetal
bovine serum (FBS) and then serially diluted in
100ml volumes in replicate wells in a microtiter tissue
culture plate to serve as stimulator cells in a 96-H allo-
p r o l i f e r a t i o na s s a ya sd e s c r i b e di nt h em e t h o d s
section. A total of 10
5 allogeneic PBMCs obtained
from two healthy donors were added to each well to
serve as responder cells. The results from these
proliferation experiments demonstrate that by 4 or 7
days cord blood derived CD34 þ cells cultured in
media supplemented with low dose (2ng/ml) GM-
CSF alone were unable to induce signiﬁcant pro-
liferative responses in PBMCs. However, by 7 day, as
few as 1000 cord blood derived CD34 þ cells
cultured in media supplemented with GM-CSF
(10ng/ml) plus IL-4 (10ng/ml), TNF-a (10ng/ml),
and LPS (1mg/ml) were able to induce signiﬁcant allo-
proliferative responses in PBMCs (Figure 1A). Thus,
it was reasoned that if plasma from mothers post
partum would normally contain such growth factors
that would promote functional maturation of pro-
genitor DCs required for normal physiologic remodel-
ing peripartum, the question remained whether such
growth factors would also be present in plasma from
PPCM patients.
Figure 1. (a) Human cord blood derived dendritic cells induce
allo-proliferation of PBMCs. Cord blood derived CD34 þ cells
were cultured in serum-free stem cell media supplemented with low
dose (2ng/ml) GM-CSF (Low) alone to promote development of
immature progenitor DC or with high dose GM-CSF (10ng/ml)
plus IL-4 (10ng/ml), TNF-a (10ng/ml) and LPS (1mg/ml) (Hi) to
promote development of mature DC. Cell (allo-) proliferation
assays (MLR) were conducted for 96h with two sets of MHC
disparate PBMC responders. Allo-proliferative responses to 7 day
cultured cord blood progenitor DCs are represented as the mean
cpm of incorporated [3H]-thymidine from triplicate cultures.
(b) PPCM plasma does not promote DC maturation. Cord blood
derived CD34 þ cells were cultured for 7 days in serum-free stem
cell media supplemented with low dose (2ng/ml) GM-CSF and
25% (v/v) plasma from control patients (n ¼ 7) or PPCM patients
(n ¼ 7) to induce differentiation and maturation of DCs.
Afterwards, in vitro differentiated DCs were cocultured with
PBMCs isolated from normal donors and allo-proliferative
responses were determined by measuring cpm of incorporated
[H
3]-thymidine as described.
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Proliferation experiments were thus subsequently
conducted with progenitor CBDCs and HLA mis-
matched PBMCs as described in the methods section.
Proliferative responses of PBMCs co-cultured with
HLA mismatched progenitor CBDCs in media
supplemented with low dose (2ng/ml) GM-CSF and
25% v/v plasma from normal non-Haitian—nullipar-
ous volunteers or pooled cord blood were below
detectable limits (data not shown). However, 7 out of
12 PPCM plasma samples and 7 out of 12 Haitian
control plasma samples did induce DC maturation as
reasoned above leading to detectable allo-proliferative
responses in PBMCs. However, of importance was the
ﬁnding that the magnitude of allo-proliferative
responses to DCs cultured in Haitian control plasma
was signiﬁcantly greater (p , 0.04) than proliferative
responses to CBDCs cultured in PPCM conditioned
media (Figure 1B).
Phenotypic characterization of CBDC maturation
by FMF
It was reasoned that the lower levels of allo-
proliferative responses to prCBDCs developed in
PPCM plasma was either due to lack of appropriate
frequency and density of MHC/co-stimulatory mol-
ecule expression or perhaps due to intrinsic properties
of the CBDCs developed in the presence of plasma
isolated from PPCM patients.In efforts to address this
issue, progenitor CBDCs were cultured in triplicate in
media supplemented with low dose (2ng/ml) GM-
CSF and 25% v/v plasma from PPCM or control
subjects (n ¼ 12). After 7 days, the cells were
harvested and the levels of cell surface expressed
molecules associated with mature DCs were measured
by FMFas described in the method section. The levels
of expression of MHC class I and II, CD80 and 86
costimulatory molecules, and CD83 and CCR7 DC
maturation antigens were all signiﬁcantly lower
(p , 0.0001) on CBDCs cultured in the presence of
PPCM plasma relative to controls (Figure 2). These
data provide further evidence that plasma from
PPCM patients as compared to plasma from control
subjects does not support prDC maturation.
Discussion
Cells of the innate arm of the immune system, such as
DCs and mast cells arise from bone-marrow derived
hematopoietic precursors. Their ontological develop-
ment and activation is determined and regulated by
environmental signals generated in part in response to
a variety of infectious and non-infectious agents.
Our hypothesis is that during normal pregnancy,
remodeling of the heart is required for return to
normal physiological status. This remodeling requires
cells of different lineages including phagocytic DCs
whose progenitors are attracted to the cardiac tissue
by the synthesis and release of a gradient of chemokine
and growth factors that induce their functional
maturation. Thus, plasma from such peri/postpartum
normal pregnant mothers contain a spectrum of such
chemokines, cytokines and growth factors able to
mediate the recruitment and development of different
populations of undifferentiated and specialized cells of
hematopoietic origin. Initially, appropriate chemo-
kines for the recruitment and development of cells
responsible for the removal of dead or dying cells and
debris are expressed followed by factors necessary for
the recruitment and development of progenitor cells
that possess the ability to participate in physiological
tissue repair and remodeling. Such precursors then
receive signals at extravascular sites of tissue injury
(i.e. the heart) that direct their lineage commitment
and maturation. In physiologic conditions these
cellular responses mediate homeostatic compensation
that helps restore normal (pre-pregnancy) cardiac
function. However, we submit that in patho-physio-
logical conditions such as in PPCM the disruption of
this normal homeostatic process of tissue remodeling
contributes to cardiac decompensation and heart
failure.
Autoimmune phenomena and pathogenic mechan-
isms have been observed and proposed for different
formsofidiopathicdilatedcardiomyopathies(IDCMs)
including PPCM (Caforio et al. 1997, Ansari et al.
Figure 2. Analysis of DC maturation markers FMF. Cord blood
derived CD34 þ cells were cultured for seven days in serum-free
stem cell media supplemented with low dose (2ng/ml) GM-CSF
and 25% (v/v) plasma from control patients (n ¼ 7) or PPCM
patients (n ¼ 7) to induce differentiation and maturation of DCs. In
vitro differentiated DCs were then subjected to FMF to determine
the relative expression antigens associated with DC maturation:
CD80, CD86, CD83, CCR7, MHC class II and MHC class
I. Levels of expression are represented as mean channel ﬂuorescence
intensity.
Dendritic cell maturation and PPCM 2712002, Sundstrom et al. 2002). Furthermore, autoanti-
bodies to speciﬁc cardiac antigens, such as anti-b1-
adrenergic receptor and anti-myosin antibodies, have
been reported to be directly involved in autoimmune
mechanisms of IDCM and PPCM (Warraich et al.
2002, Jahns et al. 2004). A role for DCs in innate
immune-mediated mechanisms and in post-infectious
autoimmune mechanisms of IDCM has also recently
been proposed (Eriksson et al. 2003). Although, the
degree to which autoimmune phenomena are involved
in PPCM remains unclear, it is ofinterest that DCs are
linked to the interface between innate and adaptive
immunity by virtue of their functional maturity.
DCs are highly specialized antigen-presenting cells.
Precursor or immature DCs are primed to sense and
respond to a wide variety of environmental signals
through a broad array of cell surface-expressed
chemokine receptors and TLRs. Immature DCs use
thesereceptorstointerrogate antigensandtonegotiate
appropriate immune responses. Immature DCs
express germ-line encoded receptors that recognize
pathogen-associated molecular patterns (PAMP)
expressed on endogenous antigens from damaged
cells, e.g. HSPs or certain bacterial or viral antigens.
Signaling through such receptors induces DC matu-
ration, including antigen processing, upregulation of
major histocompatibility class II molecules, induction
of costimulatory activity and migration to regional
lymph nodes, where they are able to prime antigen-
speciﬁc T cells (Srivastava 2002a, b). DC processing
and presentation of endogenous antigens released
during tissue injury can trigger autoreactive T cells if
theDCsareactivatedinappropriately(Turley2002).It
has been demonstrated in murine models of post-
infectious myocarditis that BALB-c mice given DCs
preloaded with cardiac speciﬁc a-myosin peptides
develop cardiomyopathy if DCs are prestimulated
with CD40L and TLR agonists. Such experimental
DC-mediated myocarditis progressed into dilated
cardiomyopathy and heart failure even after resolution
ofacuteinﬂammatoryinﬁltrates(Erikssonetal.2003).
Examination of explanted hearts (at autopsy or during
heart transplant) from PPCM patients in Haiti or in
the US as well as endomyocardial biopsies from
patients with post-infectious cardiomyopathy do not
necessarily show inﬂammatory inﬁltrates, even when
autoantibodies are present (unpublished obser-
vations). Thus, the results from murine studies are
consistent with the clinical observations from PPCM
subjects and suggest a common pathogenesis of a
possible post-infectious form of PPCM.
The hypothesis tested in this investigation was that
dysregulation of the expression of factors involved in
homeostatic physiological tissue remodeling during
the peripartum period would be manifested by a
diminished capacity of plasma from subjects with
documented PPCM to promote functional matu-
ration of progenitor DCs relative to plasma collected
from age and parity matched control subjects. The
results from in vitro studies presented in this report
convincingly show that a high frequency of PPCM
plasma showed a signiﬁcantly diminished capacity to
promote maturation of cord blood derived progenitor
DCs relative to plasma obtained from Haitian control
subjects as measured by alloproliferative responses by
PBMCs (Figure 1B). These results were not due to a
loss of viability (data not shown) and the diminished
CBDC maturation strongly correlated with the poor
expression of MCH class I/II and co-stimulatory
molecules, CD80 and 86, as well as DC maturation
antigens: CCR7 and CD83 (Figure 2) on cultured
prCBDCs. As expected, plasma biomarkers associ-
ated with cardiomyopathy and inﬂammation:
endothelin-1, proBNP and CRP, were signiﬁcantly
elevated in PPCM subjects. However, the observation
that select cytokines and growth factors involved in
DC maturation and innate immune activation were
also signiﬁcantly (GM-CSF; p , 0.008) or slightly
(TNF-a, p , 0.08 and IL-6, p , 0.06) elevated in
PPCM patients relative to control subjects (Table III)
appeared to conﬂict with data from our functional
studies that show evidence of diminished DC
maturation (Figures 1A and 2). Surprisingly, cyto-
kines that are known to inhibit immune responses,
such as TGF-b, were in fact decreased in the plasma
from PPCM patients compared to controls. These
data suggest there must be other cytokines and growth
factors that override the pro-inﬂammatory cytokines
which need to be identiﬁed. It should also be noted
that ELISA basically identiﬁes the existence of a
protein which may or may not be functional. Thus, it
could be that the maturation-inducing cytokines may
be dysfunctional. Further studies of the quantitation
of biologically functional molecules in PPCM as
compared to appropriate normal controls from Haiti
need to be performed and are in progress. Further-
more, the fact that DC maturation was observed in
in vitro culture with plasma from Haitian mothers but
not with plasma from matched cord blood or non-
Haitian male or nulliparous female volunteers also
remains unexplained. However, the question of
whether such phenomena are characteristic of all
post-partum women or only Haitian mothers was not
addressed and was beyond the scope of this
investigation. The results of this study describe a
unique clinical pattern that reﬂects an immune
environment in which DC maturation and perhaps
an even broader potential for critical progenitor cell-
mediated tissue repair and remodeling responses
are blunted in Haitian PPCM patients. Collectively,
these results also support our hypothesis that
the absence or suppression of such innate immune-
mediated responses contributes to the pathogenesis
and irreversible progression towards PPCM in
women with early stage heart disease during the
peripartum period.
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